Bausch + Lomb Corp (BLCO.TO) has seen a notable decline in its stock price this week, with market movements driven by recent product updates and sector trends.
This week, Bausch + Lomb Corp's stock has faced some turbulence, closing at C$22.96, reflecting a slight daily gain of 0.31%, but a more significant weekly drop of 5.71%. Investors are closely monitoring the company's developments in the ophthalmology sector, particularly in light of recent product announcements and market reports.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.45B
52W high
$25.70
52W low
$18.76
1W change
+3.00%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 7.3% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.39
+7.3% Upside
Current Price
C$23.66
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
35.9%
Annualized
90-Day Vol
30.9%
Annualized
Trend (90d)
+31.9%
Annualized drift
90d Mean
C$26.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.58 | C$21.72 – C$27.81 |
| 60 trading days | C$25.53 | C$21.43 – C$30.41 |
| 90 trading days | C$26.51 | C$21.40 – C$32.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Bausch + Lomb's recent product launches and market presence in ophthalmology are promising, the stock's bearish outlook and significant weekly decline may warrant caution for investors considering an entry point.
Stock Performance Overview
Bausch + Lomb's stock has experienced a mix of performance metrics, with a year-to-date increase of 0.75% but a troubling weekly decline of 5.71%.
Bull case
Bausch + Lomb is introducing innovative products like the Orphia™ AI-powered platform and has reported positive Phase 2 results for glaucoma treatments. These developments could strengthen its market position and drive future growth.
Bear case
Despite these advancements, analysts believe the stock may be trading significantly below its fair value. The bearish outlook is compounded by ongoing challenges, including a negative profit margin and low return on equity.
Recent Price Action
Advertisement
Bausch + Lomb Corp closed at C$22.96, marking a daily increase of 0.31%. However, the stock has experienced a notable decline of 5.71% over the past week, despite a 1-month increase of 8.82% and a year-to-date rise of 0.75%. This volatility reflects broader trends in the healthcare sector, which has seen declines in recent trading sessions.
Company News and Catalysts
Recent headlines have highlighted several key developments for Bausch + Lomb. Notably, the company announced positive Phase 2 results for its glaucoma neuroprotective candidate, which could bolster its portfolio in the ophthalmology market. Additionally, the launch of Orphia™, an AI-powered digital health platform, aims to enhance patient care by streamlining physician workflows. However, analysts have expressed concerns that the stock may be trading 57% below its fair value following these product updates, contributing to the recent bearish sentiment.
Technical Picture
From a technical standpoint, Bausch + Lomb is currently trading above its 50-day moving average of C$22.05, indicating a positive short-term trend (+4.1% vs price). It is also slightly above its 200-day moving average of C$22.46 (+2.2% vs price). The stock's 52-week range spans from C$18.24 to C$25.70, suggesting it is currently at 63% of its range. With a beta of 0.56, the stock exhibits lower volatility compared to the broader market. The latest trading volume of 2,154 shares is slightly below the 20-day average volume of 2,320 shares, reflecting a volume ratio of 0.93x.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
